lillydirect self pay tirzepatide Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Lilly launches lower-price weight-loss drug

Patients should discuss risks carefully if they have: A history of pancreatitis Severe nausea, vomiting, or gastroparesis Gallbladder disease Severe dehydration risk Advanced kidney disease with frequent vomiting or poor oral intake A personal or family history of medullary thyroid cancer Multiple endocrine neoplasia syndrome type 2 Pregnancy, plans for pregnancy, or breastfeeding Also, if you have active lupus nephritis or unstable lupus, your rheumatologist and nephrologist should be involved before starting any new medicine that could affect hydration, nutrition, kidney function, or medication tolerance

Following resolution of nationwide shortages, the FDA ended its temporary enforcement discretion, meaning these medications may now only be compounded under limited, legally defined circumstances . On February 21, 2025 , the U.S

The efficacy and safety profiles are equivalent

For a deeper single-compound overview, see the BPC-157 Canada research guide